Convergence Investment Partners LLC Has $2.07 Million Stake in CVS Health Corporation $CVS

Convergence Investment Partners LLC boosted its holdings in shares of CVS Health Corporation (NYSE:CVS) by 263.8% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 26,079 shares of the pharmacy operator’s stock after purchasing an additional 18,911 shares during the period. Convergence Investment Partners LLC’s holdings in CVS Health were worth $2,070,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of CVS. Caitong International Asset Management Co. Ltd increased its holdings in CVS Health by 407.2% during the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 350 shares of the pharmacy operator’s stock valued at $26,000 after purchasing an additional 281 shares in the last quarter. Ares Financial Consulting LLC acquired a new stake in CVS Health during the 4th quarter valued at $29,000. Dogwood Wealth Management LLC increased its holdings in CVS Health by 93.7% during the 4th quarter. Dogwood Wealth Management LLC now owns 370 shares of the pharmacy operator’s stock valued at $29,000 after purchasing an additional 179 shares in the last quarter. GoalVest Advisory LLC acquired a new stake in CVS Health during the 4th quarter valued at $32,000. Finally, Financial Consulate Inc. increased its holdings in CVS Health by 99.6% during the 4th quarter. Financial Consulate Inc. now owns 499 shares of the pharmacy operator’s stock valued at $40,000 after purchasing an additional 249 shares in the last quarter. 80.66% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other news, EVP Tilak Mandadi sold 69,551 shares of the firm’s stock in a transaction on Friday, May 8th. The stock was sold at an average price of $89.58, for a total value of $6,230,378.58. Following the transaction, the executive vice president directly owned 10,133 shares in the company, valued at $907,714.14. This trade represents a 87.28% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.85% of the stock is owned by corporate insiders.

CVS Health Stock Down 1.2%

Shares of CVS opened at $95.95 on Friday. The firm has a market capitalization of $122.42 billion, a price-to-earnings ratio of 42.27, a PEG ratio of 0.95 and a beta of 0.60. The company has a debt-to-equity ratio of 0.78, a quick ratio of 0.66 and a current ratio of 0.87. The business’s fifty day moving average price is $78.71 and its two-hundred day moving average price is $78.59. CVS Health Corporation has a 52 week low of $58.50 and a 52 week high of $98.43.

CVS Health (NYSE:CVS) last announced its quarterly earnings data on Wednesday, May 6th. The pharmacy operator reported $2.57 EPS for the quarter, beating analysts’ consensus estimates of $2.21 by $0.36. The firm had revenue of $100.43 billion for the quarter, compared to analyst estimates of $94.99 billion. CVS Health had a return on equity of 11.88% and a net margin of 0.72%.The business’s quarterly revenue was up 6.2% compared to the same quarter last year. During the same period last year, the company earned $2.25 EPS. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. On average, analysts predict that CVS Health Corporation will post 7.44 earnings per share for the current year.

CVS Health Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, May 4th. Stockholders of record on Thursday, April 23rd were given a $0.665 dividend. This represents a $2.66 annualized dividend and a dividend yield of 2.8%. The ex-dividend date was Thursday, April 23rd. CVS Health’s dividend payout ratio (DPR) is currently 117.18%.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on CVS. Wall Street Zen raised CVS Health from a “hold” rating to a “buy” rating in a report on Saturday, May 9th. Wells Fargo & Company raised their price target on CVS Health from $102.00 to $103.00 and gave the company an “overweight” rating in a report on Friday, May 8th. Robert W. Baird increased their price objective on CVS Health from $92.00 to $94.00 and gave the company an “outperform” rating in a research report on Wednesday, April 15th. DA Davidson increased their price objective on CVS Health from $80.00 to $100.00 and gave the company a “buy” rating in a research report on Thursday, May 7th. Finally, HSBC increased their price objective on CVS Health from $83.00 to $85.00 and gave the company a “hold” rating in a research report on Tuesday, May 5th. Twenty-two equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $98.08.

Key Headlines Impacting CVS Health

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: Morgan Stanley raised its price target on CVS Health and kept an overweight rating, signaling confidence in further upside after the company’s stronger-than-expected quarterly results. Morgan Stanley Issues Positive Forecast for CVS Health (NYSE:CVS) Stock Price
• Positive Sentiment: Argus also lifted its outlook for CVS Health, adding to the wave of analyst support that may be helping shares move higher. Argus Issues Positive Forecast for CVS Health (NYSE:CVS) Stock Price
• Positive Sentiment: CVS reported solid Q1 2026 earnings recently, beating estimates on both revenue and adjusted EPS, which continues to drive investor optimism about execution and valuation. Here is Why CVS Health (CVS) is One of the Cheap Stocks to Buy For the Next 10 Years
• Positive Sentiment: CVS and WGU launched an online pre-pharmacy degree program to help build a stronger pharmacist pipeline, a move that could support long-term staffing and service growth. CVS Health® and WGU launch online pre-pharmacy degree program for future pharmacists nationwide
• Neutral Sentiment: CVS advanced its portfolio reset by selling Omnicare after bankruptcy court approval, which simplifies the business and removes an underperforming unit, but also confirms ongoing restructuring. CVS Refocuses On Core Health Platform With Omnicare Sale And Drone Rollout
• Neutral Sentiment: CVS also highlighted community and brand-building initiatives in Rhode Island, including its economic impact report and expanded WIC acceptance, which are positive for reputation but less likely to move the stock on their own. CVS Health’s Annual Impact in Rhode Island

CVS Health Company Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.